NASDAQ:CELCCelcuity Stock Price, Forecast & News Adding Choose a watchlist: Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Celcuity Inc Please log in to your account or sign up in order to add this asset to your watchlist. Log In and Add $5.93 -0.37 (-5.87 %) (As of 07/13/2020 04:00 PM ET) Add Compare Share Today's Range$5.54Now: $5.93▼$6.4650-Day Range$5.93MA: $8.27▼$11.0452-Week Range$4.03Now: $5.93▼$23.93Volume44,800 shsAverage Volume22,517 shsMarket Capitalization$60.92 millionP/E RatioN/ADividend YieldN/ABeta0.97 ProfileAnalyst RatingsAdvanced ChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsSocial Media Celcuity Inc., a cellular analysis company, discovers cancer sub-types and commercializes diagnostic tests to enhance the clinical outcomes of cancer patients treated with targeted therapies in the United States. The company's CELx diagnostic platform uses a patient's living tumor cells to identify the specific abnormal cellular process driving a patient's cancer and the targeted therapy that treats it. It is developing CELx HSF test to diagnose two new sub-types of HER2-negative breast cancer. The company is also developing CELx MP test to diagnose 12 new potential cancer sub-types in breast, lung, colon, ovarian, kidney, and bladder cancers. Celcuity Inc. was founded in 2011 and is headquartered in Minneapolis, Minnesota.Read More Beat the Market (BTM) Rank™ 3.5 Analyst's Opinion Consensus RatingCelcuity has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 2 buy ratings, no hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $11.00, Celcuity has a potential upside of 85.5% from its current price of $5.93.Amount of Analyst CoverageCelcuity has only been the subject of 2 research reports in the past 90 days. Previous Next 2.5 Community Rank Outperform VotesCelcuity has received 296 “outperform” votes. (Add your “outperform” vote.)Underperform VotesCelcuity has received 299 “underperform” votes. (Add your “underperform” vote.)Community SentimentCelcuity has received 50.25% “underperform” votes from our community.MarketBeat's community ratings are surveys of what our community members think about Celcuity and other stocks. Vote “Outperform” if you believe CELC will outperform the S&P 500 over the long term. Vote “Underperform” if you believe CELC will underperform the S&P 500 over the long term. You may vote once every thirty days. Previous Next 0.0 Dividend Strength Dividend YieldCelcuity does not currently pay a dividend.Dividend GrowthCelcuity does not have a long track record of dividend growth. Previous Next 1.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Celcuity insiders have not sold or bought any company stock.Percentage Held by Insiders43.50% of the stock of Celcuity is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by InstitutionsOnly 22.00% of the stock of Celcuity is held by institutions. Previous Next 0.0 Earnings and Valuation Earnings GrowthEarnings for Celcuity are expected to decrease in the coming year, from ($0.81) to ($0.84) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Celcuity is -7.80, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Celcuity is -7.80, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioCelcuity has a P/B Ratio of 3.15. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next Analyst Opinion: 3.5Community Rank: 2.5Dividend Strength: 0.0Insider Behavior: 1.0Valuation: 0.0 5 -4 -3 -2 -1 -Overall Beat the Market Rank™1.40 out of 5 stars Industry, Sector and Symbol Stock Exchange NASDAQ Industry Medical laboratories Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:CELC Previous Symbol CUSIPN/A CIK1603454 Webwww.celcuity.com Phone763-392-0767Debt Debt-to-Equity RatioN/A Current Ratio20.16 Quick Ratio20.16Price-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$1.88 per share Price / Book3.15Profitability EPS (Most Recent Fiscal Year)($0.72) Net Income$-7,360,000.00 Net MarginsN/A Return on Equity-38.84% Return on Assets-37.01%Miscellaneous Employees26 Outstanding Shares10,274,000Market Cap$60.92 million Next Earnings Date8/13/2020 (Estimated) OptionableNot Optionable NASDAQ:CELC Rates by TradingView Receive CELC News and Ratings via Email Sign-up to receive the latest news and ratings for CELC and its competitors with MarketBeat's FREE daily newsletter. Celcuity (NASDAQ:CELC) Frequently Asked Questions How has Celcuity's stock been impacted by COVID-19 (Coronavirus)? Celcuity's stock was trading at $7.12 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization (WHO). Since then, CELC shares have decreased by 16.7% and is now trading at $5.93. View which stocks have been most impacted by Coronavirus. Do Wall Street analysts recommend investors buy shares of Celcuity? 2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Celcuity in the last year. There are currently 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Celcuity. When is Celcuity's next earnings date? Celcuity is scheduled to release its next quarterly earnings announcement on Thursday, August 13th 2020. View our earnings forecast for Celcuity. How were Celcuity's earnings last quarter? Celcuity Inc (NASDAQ:CELC) released its quarterly earnings data on Thursday, May, 7th. The company reported ($0.22) earnings per share for the quarter, missing the Zacks' consensus estimate of ($0.20) by $0.02. View Celcuity's earnings history. What price target have analysts set for CELC? 2 Wall Street analysts have issued twelve-month price objectives for Celcuity's shares. Their forecasts range from $11.00 to $11.00. On average, they expect Celcuity's stock price to reach $11.00 in the next twelve months. This suggests a possible upside of 85.5% from the stock's current price. View analysts' price targets for Celcuity. Has Celcuity been receiving favorable news coverage? News stories about CELC stock have been trending very negative on Tuesday, according to InfoTrie Sentiment Analysis. The research group rates the sentiment of news coverage by analyzing more than six thousand blog and news sources in real-time. The firm ranks coverage of public companies on a scale of negative five to five, with scores closest to five being the most favorable. Celcuity earned a media sentiment score of -3.2 on InfoTrie's scale. They also assigned press coverage about the company a news buzz of 0.0 out of 10, meaning that recent news coverage is extremely unlikely to have an impact on the company's share price in the next several days. View the latest news about Celcuity. Are investors shorting Celcuity? Celcuity saw a increase in short interest in the month of June. As of June 30th, there was short interest totaling 146,000 shares, an increase of 63.3% from the June 15th total of 89,400 shares. Based on an average daily volume of 22,700 shares, the days-to-cover ratio is currently 6.4 days. Approximately 2.9% of the company's stock are sold short. View Celcuity's Current Options Chain. Who are some of Celcuity's key competitors? Some companies that are related to Celcuity include DermTech (DMTK), Enzo Biochem (ENZ), Biocept (BIOC), Anpac Bio-Medical Science (ANPC), Miragen Therapeutics (MGEN), OpGen (OPGN), Psychemedics (PMD), Avant Diagnostics (AVDX), PotNetwork (POTN), CBA Florida (CBAI), Cancer Genetics (CGIX), First Choice Healthcare Solutions (FCHS) and Aeon Global Health (AGHC). View all competitors. What other stocks do shareholders of Celcuity own? Based on aggregate information from My MarketBeat watchlists, some companies that other Celcuity investors own include Bank of Hawaii (BOH), InterDigital Wireless (IDCC), Stag Industrial (STAG), Evoke Pharma (EVOK), Amicus Therapeutics (FOLD), Allena Pharmaceuticals (ALNA), NovaBay Pharmaceuticals (NBY), Ring Energy (REI), Ring Energy (REI) and Consolidated Edison (ED). Who are Celcuity's key executives? Celcuity's management team includes the following people: Mr. Brian F. Sullivan, Co-Founder, Chairman & CEO (Age 57)Dr. Lance G. Laing, Co-Founder, Chief Science Officer, VP, Sec. & Director (Age 57)Ms. Vicky Hahne, Chief Financial Officer (Age 53)Ms. Laura Beggrow RN, Chief Commercial Officer (Age 56)Mr. Larry Fitzgerald, VP of Strategic Partnerships & Managed Markets (Age 48) When did Celcuity IPO? (CELC) raised $18 million in an initial public offering (IPO) on Wednesday, September 20th 2017. The company issued 2,000,000 shares at $8.00-$10.00 per share. Craig-Hallum Capital Group acted as the underwriter for the IPO. What is Celcuity's stock symbol? Celcuity trades on the NASDAQ under the ticker symbol "CELC." How do I buy shares of Celcuity? Shares of CELC can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. What is Celcuity's stock price today? One share of CELC stock can currently be purchased for approximately $5.93. How big of a company is Celcuity? Celcuity has a market capitalization of $60.92 million. The company earns $-7,360,000.00 in net income (profit) each year or ($0.72) on an earnings per share basis. Celcuity employs 26 workers across the globe. What is Celcuity's official website? The official website for Celcuity is www.celcuity.com. How can I contact Celcuity? Celcuity's mailing address is 16305 36TH AVENUE NORTH SUITE 100, MINNEAPOLIS MN, 55446. The company can be reached via phone at 763-392-0767. This page was last updated on 7/14/2020 by MarketBeat.com Staff 30 Days of MarketBeat All Access for $1.00 Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your Risk-Free Trial Subscription Here Questions? Get Started with MarketBeat — Read Your Daily NewsletterCheck Out My MarketBeatWatch Our Tutorial VideosAdd a Stock to Your WatchlistSet Up an Instant AlertView a Company's Profile PageView Our Financial CalendarsView Today's Analyst Ratings
